Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Hansoh Pharmaceutical Group has received approval from China’s National Medical Products Administration to conduct clinical trials for its new antibody-drug conjugate, HS-20110, aimed at treating advanced solid tumors. This development marks a significant step in the company’s innovation efforts, potentially impacting its market position.
For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.